Alvotech (NasdaqGM:ALVO) just picked up two meaningful regulatory milestones, including FDA sign off on a higher output process for its Humira biosimilar and a first of its kind European filing for an Eylea 8 mg biosimilar.
Those approvals landed after a volatile run for Alvotech, with the share price climbing 49.03% over the past 90 days despite a 19.65% decline over 30 days and a 43.17% drop in 1 year total shareholder return. The recent pullback around the current US$4.62 level suggests investors are reassessing risk after a strong short term rebound. At the same time, fresh regulatory milestones hint at changing expectations for the business’s longer term opportunity set.
Scan how Alvotech compares with other high-potential biopharma plays by reviewing our hand picked 21 high quality undiscovered gems in the current market reset.
After a sharp 90 day bounce but a weak 1 year return, Alvotech now sits in that awkward middle ground. Is it early to pay up, or risky to wait for a cleaner entry and miss it?
Most Popular Narrative: 32% Undervalued
Against Alvotech's last close at $4.62, the most followed narrative anchors fair value at $6.80 and leans on a relatively low 8.58% discount rate. This places significant emphasis on the execution of the biosimilar pipeline.
Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.
See why 14 investors see Alvotech as 32% undervalued.
The narrative ties that upside view to several moving parts. Forecasts build in revenue reaching $976.3 million and earnings of $223.1 million by 2029, with profit margins assumed to flip from current losses to 22.9% and the stock trading on a future P/E of 17.1x. On those numbers, the $6.80 fair value sits between a bullish $9.00 and a cautious $4.00 analyst target range, which leaves room for very different opinions on how the story plays out.
On the risk side, the same storyline flags that Alvotech leans heavily on milestone payments and partner performance, with high fixed costs, negative equity and all liabilities funded from higher risk sources rather than deposits. Pricing pressure in Humira and Stelara biosimilars, plus regulatory timing around FDA and other agencies, are central to whether those long term cash flow assumptions hold up or need to be cut back.
For context, the SWS DCF model currently points to a future cash flow value of $24.77, which is much higher than both the $6.80 narrative fair value and the present share price. That gap reflects very optimistic cash flow projections and a long runway of expected growth, so it is worth stress testing those inputs against your own view on biosimilar competition, partner concentration and Alvotech's balance sheet flexibility.
Result: Fair Value of $6.80 (UNDERVALUED)
Still, two pressure points could flip this Alvotech narrative quickly: tougher biosimilar price competition and any fresh delays around key FDA or partner milestones.
Find out about the key risks to this Alvotech narrative.
Next Steps
Mixed signals around Alvotech's potential and risk profile can be hard to weigh. Move quickly, pull up the numbers yourself, and pressure test both the upside and downside using the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Alvotech?
If Alvotech has your attention but you want a broader watchlist too, now is the time to scan other focused opportunities before the crowd catches up.
- Target steadier compounding potential by reviewing companies with rich cash flow support and valuation upside in our 29 high quality undervalued stocks.
- Build a more resilient core by filtering for balance sheets that can absorb shocks using the list of solid balance sheet and fundamentals (24 results).
- Hunt for tomorrow's potential standouts early by scanning the 30 resilient stocks with low risk scores before those profiles attract wider attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com